CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended		74 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013
CASH FLOW FROM OPERATING ACTIVITIES
Net loss	$ (1,083,246)	$ (1,310,065)	$ (13,214,531)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization	80,312	96,612	1,057,047
Technology impairment	0	345,000	690,000
Common stock issued for services	0	18,500	318,500
Stock options and warrants	29,557	34,067	3,043,311
(Increase) decrease in assets
Prepaid drug product for testing	(84,180)	(142,477)	(279,180)
Other current assets	(3,836)	1,950	(46,411)
Increase (decrease) in liabilities
Accounts payable and accrued expenses	(61,388)	(73,108)	267,856
Net cash used in operating activities	(1,122,781)	(1,029,521)	(8,163,408)
CASH FLOW FROM INVESTING ACTIVITIES
Purchase of exclusive license - related party	0	(25,000)	(884,710)
Net cash used in investing activities	0	(25,000)	(884,710)
CASH FLOW FROM FINANCING ACTIVITIES
Proceeds from convertible notes	0	0	435,000
Cash repayment of convertible notes	0	0	(15,000)
Net proceeds from sale of common stock	2,515,961	264,709	10,555,344
Net cash from financing activities	2,515,961	264,709	10,975,344
NET INCREASE (DECREASE) IN CASH	1,393,180	(789,812)	1,927,226
Cash, beginning of period	534,046	952,252	0
Cash, end of period	1,927,226	162,440	1,927,226
Cash paid for
Interest	0	0	445
Income taxes	0	0	0
Non-cash financing activities
Common stock issued upon conversion of convertible notes	0	0	420,000
Placement Agent
Non-cash financing activities
Common stock issued	448,950	0	1,040,516
MD Anderson for License
Non-cash financing activities
Common stock issued	0	0	2,354,167
LPC
Non-cash financing activities
Common stock issued	$ 0	$ 1,750	$ 210,755